Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q1 2020 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2019 Net Income-$17.75K-$17.75KN/M vs Q1 2019 EPS Diluted$0.00$0.00— vs Q1 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
Operating Cash Flow$893−41.1% ended Apr 30, 2020 · filed Jun 19, 2020 · 50 d after period end